OncoTherapy Science Balance Sheet Health
Financial Health criteria checks 5/6
OncoTherapy Science has a total shareholder equity of ¥999.0M and total debt of ¥0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are ¥1.5B and ¥549.0M respectively.
Key information
0%
Debt to equity ratio
JP¥0
Debt
| Interest coverage ratio | n/a |
| Cash | JP¥1.10b |
| Equity | JP¥999.00m |
| Total liabilities | JP¥549.00m |
| Total assets | JP¥1.55b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 30O's short term assets (¥1.5B) exceed its short term liabilities (¥421.0M).
Long Term Liabilities: 30O's short term assets (¥1.5B) exceed its long term liabilities (¥128.0M).
Debt to Equity History and Analysis
Debt Level: 30O is debt free.
Reducing Debt: 30O has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 30O has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 30O has less than a year of cash runway if free cash flow continues to grow at historical rates of 17% each year.